Read Original Release

University asks readers to take leap of faith that antibiotic tested only in the lab is a ‘breakthrough’

Scientists make significant breakthrough on superbug-killing antibiotic teixobactin

Our Review Summary

MRSANew antibiotics are desperately needed, but an advance in the synthesis of a new antibiotic should not be called a breakthrough when the drug has yet to be tested in people. This release neglects to tell readers that all the claims are based on only laboratory tests. There is little acknowledgment of the uncertainties and challenges ahead. This research report is of great interest to drug researchers, but its relevance to practicing clinicians and the general public is not yet known.


Why This Matters

Only a fraction of a percent of experimental drugs that produce positive laboratory test results survive the hurdles of animal and human testing. Especially when the need is so great, as is the case with antibiotic resistant infections, news releases should not proclaim success prematurely.


Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

A key point of the release is that the researchers have developed a form of the teixobactin antibiotic that could be commercially viable. This statement implies that they made some rough calculations of the potential cost of manufacturing the drug. Even though it may be too early to guess at a market price (which depends on many factors other than actual manufacturing cost), it would have been nice to see some comparison to the production costs of other antibiotics.

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

The release says the simplified versions of teixobactin “have identical potency” to the natural form. A quote also claims teixobactin “kills bacteria without detectable resistance including superbugs such as MRSA.” But nowhere are readers told that teixobactin has yet to be tested in people. All the claims of benefits are based on laboratory tests. Readers should be told that the benefits for patients have not yet been tested.

As one commentary about new antibiotics published last spring noted, “Resistance development may not have been observed in initial experiments yet, but similar beliefs for e.g. vancomycin, have been proven wrong. As of yet, teixobactin has not yet reached testing in clinical trials.”

Does the news release adequately explain/quantify the harms of the intervention?

Not Satisfactory

The release does not address potential harms. This omission is another reason the release should have made clear that although the researchers performed some laboratory tests for potential toxicity, teixobactin has not been tested in people, so its potential adverse effects are not known.

Does the news release seem to grasp the quality of the evidence?

Not Satisfactory

By neglecting to tell readers that the claims (which were not backed up by any numbers) are based entirely on laboratory tests, not tests in people with infections, the release may mislead many readers. The current evidence appears to be limited to in vitro studies in which the antibiotics were put into a test tube with the bacteria.

Does the news release commit disease-mongering?


The release doesn’t disease monger. There is no doubt that antibiotic resistant infections are a widespread and growing threat.

Does the news release identify funding sources & disclose conflicts of interest?

Not Satisfactory

The release does not discuss either funding or conflicts of interest. Readers would have to go to the journal article to learn:

  • the work was funded by the University of Lincoln, the Royal Society, the Rosetrees Trust and the Biotechnology and Biological Sciences Research Council (BBSRC).
  • Novobiotic Pharmaceuticals, LLC provided natural teixobactin.
  • The researchers declared no conflict of interest.

Since other researchers investigating teixobactin have submitted patent applications and commercialization of basic research has become a routine part of academic science, it would have been nice to see this news release directly address the potential financial interest the researchers may have in the development of their work.

Does the news release compare the new approach with existing alternatives?

Not Satisfactory

It appears that the release compares teixobactin to existing antibiotics, but it does not tell readers that the comparison is laboratory studies versus real world experience, which is not a fair comparison.

Does the news release establish the availability of the treatment/test/product/procedure?


The release states that this work is a step closer toward creating drug treatments. There are no claims about how long subsequent testing and development may take. However, the failure to point out that this work is confined to laboratory tests and that human clinical trials have yet to begin implies a shorter path to potential clinical use than seems likely.

Does the news release establish the true novelty of the approach?


The release states that the researchers created versions of the teixobactin antibiotic that can be produced far more quickly and efficiently than the natural form. It also notes that this announcement builds on research done over the past 18 months.

Does the news release include unjustifiable, sensational language, including in the quotes of researchers?

Not Satisfactory

The news release writers call this work a “breakthrough.” That’s what they also said in a release about an earlier research report from the researchers last June. Release writers were a bit more measured in a release issued in January, calling a research report from the team a “significant step.”

Total Score: 3 of 10 Satisfactory


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.